The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.
Alzheimer’s disease is a progressive brain disorder that affects memory, thinking, and behavior. It is the most common cause of dementia, a group of disorders that affect cognitive abilities. Alzheimer’s typically starts with mild memory loss and gradually worsens over time, eventually leading to the inability to carry out simple tasks, confusion, and disorientation. It is a degenerative disease that affects the brain cells, leading to the loss of connectivity and death of neurons, which causes the symptoms mentioned above. The cause of Alzheimer’s disease is not fully understood, but it is thought to be a combination of genetic, lifestyle, and environmental factors. There is no cure for Alzheimer’s disease, but there are treatments available to help manage symptoms and improve quality of life.